Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index

Figure 1 Correlation between BMI and DAPSA and serum IL-17 levels in PsA obese and non-obese patients.(A) Correlation between BMI and DAPSA by Kendall's tau coefficient and Spearman's rho tests (*statistical significance is for values of 0.05, one tail).(B) Graphical representation of correlation between BMI and DAPSA by Spearman test.(C) Analysis of serum levels of IL-17 in 20 obese and 20 obese and 20 non-obese patients compared to 30 healthy controls.BMI, body mass index; HC, health control; IL, interleukin; PsA, psoriatic arthritis.